<DOC>
	<DOCNO>NCT01138215</DOCNO>
	<brief_summary>To study immunogenicity , safety efficacy varicella-zoster virus vaccine HIV-infected child .</brief_summary>
	<brief_title>The Immunogenicity Varicella-zoster Virus Vaccine HIV-infected Children</brief_title>
	<detailed_description>VZV cause two clinical disease , primary infection result varicella ( chickenpox ) virus latent dorsal root ganglion . Reactivation VZV result herpes zoster ( shingle ) year decade . Immunocompetent child , varicella generally mild self limit illness . In HIV infect child , VZV often severe illness progressive varicella characterize continue eruption lesion high fever persist second week , well encephalitis , hepatitis pneumonia develop . Zoster immunocompromised patient become disseminated lesion appear outside primary dermatome visceral complication cause recurrence herpes zoster . VZV illness patient immunodeficiency disorder require admission hospital use antiviral drug . Sometimes , antiviral drug fails immunocompromised child . Passive immunization varicella zoster-immunoglobulin ( VZIG ) , administer within three day exposure , effective prevent disease reduce severity illness susceptible immunocompromised person . About half case varicella immunocompromised child occur without recognised exposure VZV . Both severe fatal varicella document despite appropriate immunoprophylaxis withVZIG . Furthermore , VZIG expensive short supply . These limitation make passive immunization less optimum strategy prevent chickenpox . Permanent protection provide administer vaccine high-risk person would preferable . Sartori AM. , University Sao Paolo Sep 2004 find give two dos varicella vaccine 41 susceptible HIV-infected childrens CDC class N1 A1 . Seroconversion occur 53 % 60 % vaccine one two dos , respectively . No significant fall CD4 T lymphocytes increase HIV viral load eight week vaccination . Saro H. Armenian , University Southern California Nov 2005 administrate single dose live varicella vaccine 10 HIV infect child . After vaccination , positive VZV-LPA response detect 50 % patient week 2 100 % week 4 , remain positive 90 % week 52 . VZV IgG detect 11 % week 2 , 67 % week 8 , 33 % week 52 . Myron J. Levin , University Colorado June 2006-2008 study safety immunogenicity vaccine varicella-zoster virus ( VZV ) naive , HIV-infected child moderate symptom and/or pronounce past current decrease CD4+ T cell count . Recipients ( 97 child ) stratify 3 group : group I - CDC category 1 immunologic category 1 ( least affect group HIV-infected child ) , group II - CDC category A , B , N immunologic category 2 ( CD4 % = 15-24 ) , group III : CDC category C and/or immunologic category 3 , least 3 month prior vaccination , achieve clinical category A N equivalent immunologic category 1 ( CD4 % = 25 ) . After 2 dos vaccine , 79 % child develop VZV-specific antibody and/or CMI 2 month vaccine 83 % responder 1 year vaccination . Bekker V. , Emma Children 's Hospital , Netherland Nov 2006 administer 2 dos varicella vaccine 15 VZV-seronegative HIV-1 infected child ( total lymphocyte count &gt; 700 lymphocytes/microl ) 6 HIV-negative VZV-seronegative . Only 60 % HIV-1 infected child VZV-specific Ab two immunization , 100 % sibling seroconverted . Thai HIV infect child usually start antiretroviral late due limit access care severe suppress immune status child develop country . Moreover , VZV vaccine country guideline still expensive . We would like provide VZV prevention group child evaluate VZV antibody response Thai HIV child VZV vaccination .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Chickenpox</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>1 . HIVinfected child . 2 . Aged 1 15 year . 3 . CD4 T lymphocyte percentage ≥ 15 % ≥ 200 cell/ml within 6 month time enrollment . 4 . Written inform consent obtain child 's parent guardian enrollment . 5 . HIVinfected child age 7 year old sign assent . 1 . History clinical varicella zoster . 2 . History exposure VZV within 1 month study entry . 3 . Received varicella vaccine . 4 . Received immunoglobulin blood product within 3 month study entry . 5 . Using oral steroid immunosuppressive drug within 3 month study entry . 6 . History hypersensitivity vaccine component ( Neomycin ) .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>varicella-zoster virus vaccine</keyword>
	<keyword>varicella-zoster virus antibody</keyword>
	<keyword>immunogenicity</keyword>
	<keyword>safety efficacy</keyword>
	<keyword>HIV-infected child</keyword>
	<keyword>Assess protective VZV Antibody</keyword>
	<keyword>Adverse event VZV vaccine</keyword>
</DOC>